CD99Targeted Irinotecan Containing Nanoparticles Show Twenty-Fold Greater Anti-Tumor Effect Than Free Irinotecan For Treatment of EwingSarcoma
Hyung Gyoo Kang, Sheetal A. Mitra, Bryon Upton, Jean Hugues Parmentier, Anahit Hovsepyran, Jon O. Nagy, Timothy Triche
This paper evaluates NV103, a CD99-targeted irinotecan nanoparticle, showing 20-fold greater antitumor effect than free irinotecan in Ewing sarcoma with no toxicity.
bioRxiv · Jan 6, 2026 · PreprintCancer Biology